Results 11 to 20 of about 24 (21)

Impact of a Multimodal Strategy Combining a New Standard of Care and Restriction of Carbapenems, Fluoroquinolones and Cephalosporins on Antibiotic Consumption and Resistance of Pseudomonas aeruginosa in a French Intensive Care Unit

International Journal of Antimicrobial Agents, 2019
Sylvain Diamantis, Salam Abbara
exaly  

Carbapenems and Pseudomonas aeruginosa: Mechanisms and Epidemiology

2020
Vanessa Silva, Gilberto Igrejas, Patrícia Poeta   +2 more
exaly  

Therapeutic Management of Bloodstream Infection Resulting From Pseudomonas aeruginosa That Is Non-Susceptible to Carbapenems but Susceptible to Cephalosporins And/Or to Penicillins

Open Forum Infectious Diseases, 2016
Mor Dadon, Ronit Zaidenstein, Hadas Ofer-Friedman   +2 more
exaly  

Heteroresistance to Carbapenems in Invasive Pseudomonas aeruginosa Infections

International Journal of Antimicrobial Agents, 2018
Xiaojiong Jia, Jianchun He, Shuangshuang Yang   +2 more
exaly  

Synergistic Combination of Carbapenems and Colistin Against P. Aeruginosa and a. Baumannii

Open Journal of Medical Microbiology, 2013
Ziad Daoud
exaly  

Dissemination Multi-Drug and Carbapenems Resistant Pseudomonas aeruginosa Among Clinical Isolates in Najaf Hospitals

Al-Kufa University Journal for Biology, 2017
exaly  

Reduction in Fluoroquinolone Use Following Introduction of Ertapenem Into a Hospital Formulary Is Associated With Improvement in Susceptibility of Pseudomonas aeruginosa to Group 2 Carbapenems: A 10-Year Study.

Antimicrobial Agents and Chemotherapy, 2011
Shemra Rizzo, Paul P Cook
exaly  

[Change in Antimicrobial Susceptibility of Pseudomonas aeruginosa Under Restricted Use of Carbapenems].

Journal of the Japanese Association for Infectious Diseases, 2008
Hiroaki Miyazaki
exaly  

Does Ertapenem Alter the Susceptibility of Pseudomonas aeruginosa to Carbapenems?

Journal of Chemotherapy, 2011
exaly  

Optimizing Intravenous Fosfomycin Dosing in Combination With Carbapenems for Treatment of Pseudomonas aeruginosa Infections in Critically Ill Patients Based on Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation

International Journal of Infectious Diseases, 2016
exaly